XOMA Royalty Corporation (XOMA)

Ligand Pharmaceuticals announced a definitive agreement to acquire XOMA Royalty for $39.00 per share in cash. XOMA Royalty reported its 2025 financial results, highlighting over $50 million in cash receipts for the full year. XOMA Royalty declared quarterly preferred stock dividends. XOMA Royalty announced the closing of its tender offer and completed the acquisition of Generation Bio, Inc. In 2025, XOMA Royalty completed seven acquisitions. Over the past year, XOMA's stock price has increased by 75.87%.

XOMA Royalty's revenue streams are primarily derived from milestone payments and royalties, and its financial performance is more likely influenced by the clinical development progress, regulatory approvals, and commercial success of the underlying licensed assets, rather than seasonal fluctuations in demand.

XOMA Royalty Corporation operates as a biotechnology royalty aggregator, acquiring economic rights to future milestone and royalty payments associated with therapeutic candidates licensed to pharmaceutical or biotechnology companies. This provides non-dilutive, non-recourse funding to the sellers. XOMA Royalty's portfolio includes economic rights to several commercial assets and focuses on early to mid-stage clinical assets.

XOMA Royalty Corporation operates in the United States, Switzerland, the Asia Pacific region, and Australia. Its headquarters are located in Emeryville, California, United States.

XOMA Royalty has established a reputation as a biotechnology royalty aggregator that provides non-dilutive, non-recourse funding to biotech companies. XOMA Royalty has also gained recognition for its strategy of acquiring "zombie" biotechs, aiming to return cash to shareholders of the distressed biotechs and profit by selling the remaining intellectual property.

XOMA Royalty Corporation has a significant institutional ownership base, with 76 institutional owners and shareholders holding a total of 8,690,053 shares as of May 6, 2026. Baker Brothers Life Sciences Capital GP LLC is noted as the largest individual shareholder, owning 13.61 million shares, representing 114.28% of the company. Xoma Royalty is owned by 72.52% institutional shareholders and 300.93% Xoma Royalty insiders.